Iovance Biotherapeutics Inc. (NASDAQ:IOVA) price is hovering lower on Tuesday, September 19, dropping -2.95% below its previous close.
A look at today’s price movement shows that the recent level at last check reads $5.93, with intraday deals fluctuating between $5.43 and $6.18. Taking into account the 52-week price action we note that the stock hit a 52-week high of $10.85 and 52-week low of $4.41. The stock subtracted -5.19% on its value in the past month.
Iovance Biotherapeutics Inc., which has a market valuation of $1.26 billion. Analysts tracking IOVA have forecast the quarterly EPS to shrink by -0.45 per share this quarter, while the same analysts predict the annual EPS to hit -$1.88 for the year 2023 and up to -$1.43 for 2024. In this case, analysts estimate an annual EPS growth of 24.50% for the year and 23.90% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $4.19 million, with the likely lows of $250k and highs of $19.75 million. Staying with the analyst view, there is a consensus estimate of $11.11 million for the company’s annual revenue in 2023.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give IOVA a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 13 analysts have assigned IOVA a recommendation rating as follows: 1 rate it as a Hold; 10 advise Buy while 2 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Iovance Biotherapeutics Inc. (IOVA) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that IOVA’s price is at present -3.16% off the SMA20 and -15.34% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 45.05, with weekly volatility standing at 14.99%. The indicator jumps to 6.69% when calculated based on the past 30 days. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s beta value is holding at 0.09, while the average true range (ATR) indicator is currently reading 0.49. Considering analysts have assigned the stock a price target range of $14.00-$38.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $22.36. Based on this estimate, we see that today’s price at last check is roughly -143.06% off the estimated low and -559.72% off the forecast high. Investors will no doubt be excited to see the share price fall to $20.00, which is the median consensus price, and at that level IOVA would be -247.22% from recent price.
Turning out attention to how the Iovance Biotherapeutics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: IOVA’s stock is -2.95% on the day and -46.91% in the past 12 months, while Pfizer Inc. (PFE) traded 0.10% in the latest session and is positioned -26.84% down on its price 12 months ago. Another comparison is with Merck & Co. Inc. (MRK) whose stock price is down -0.32% in the current trading session, and has flourished 22.53% over the past year. Elsewhere in the market, the S&P 500 Index has stumbled -0.67% in today’s early trading, with the Dow Jones Industrial also seeing a negative session so far with -0.68%.
An analysis of the Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock in terms of its daily trading volume indicates that the 3-month average is 6.01 million. However, this figure increases on the past 10-day timeline to an average of 12.2 million.
Current records show that the company has 247.78M in outstanding shares. The insiders’ percentage holdings are 0.10% of outstanding shares while the percentage share held by institutions stands at 91.41%. The stats also highlight that short interest as of Aug 30, 2023, stood at 30.07 million shares, which puts the short ratio at the time at 7.2. From this we can glean that short interest is 12.14% of company’s current outstanding shares. Notably, we see that shares short in August rose slightly given the previous month’s figure stood at 27.55 million. But the -9.94% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.